News

A severe decline in the use of estrogen therapy (ET) due to misunderstanding the findings of the Women’s Health Initiative (WHI) Estrogen Plus Progestin Trial has particularly affected hysterectomized women in their 50s, leading to excess mortality, according to a study published online in the American Journal of Public Health.

Meanwhile, the data collected isn't exactly in the right format for secondary use

Partners provide education and boots on the ground to improve health and attract members

Financial incentives will be linked to comprehensive care which includes the mind and body

CMS has increased the number of telehealth services it will reimburse under Medicare

State-level data shows potential cost savings when patients follow regimens

Provider relationships are essential to help patients self-manage clinical risks

MCOs are looking at each segment separately to assess opportunities for small business

Modernize delivery models and help PCPs do more now and in the future

CDC defines risk factors

WellPoint's RBP model puts market forces to work

A combination of diabetes, hypertension and dyslipidemia is the telltale sign of high risk

CoOportunity offers narrow- and tiered-network products, but don't call them HMOs

New OIG report reveals dieticians and massage therapists prescribing drugs and says plans have obligation to verify claims

Physicians have yet to master the implications of genetic test and their relationship to treatment, while plans await outcome evidence

A recent Supreme Court Decision underscores the necessity of counsel reviewing the dispute resolution terms in health plan contracts with providers

Plans have to promote the value of health coverage to overcome the noise about rate shock

FDA sent out a MedWatch warning, on July 12, 2013, after Medtronic recalled its MiniMed Paradigm insulin infusion sets.

A new retrospective case-control study among patients with chronic obstructive pulmonary disease (COPD) found a 30% decreased risk of COPD exacerbation with any statin use.

Patients taking the new generation of oral anticoagulants (nOACs) are associated with a significantly higher risk of gastrointestinal bleeding (GIB), according to a new study.

FDA advisers recommended in early June the easing of restrictions on the diabetes drug rosiglitazone (Avandia, GlaxoSmithKline), following an independent re-examination of GSK’s RECORD study conducted by Duke Clinical Research Institute.

Telmisartan and valsartan, used to reduce blood pressure in people with diabetes, are associated with a lower risk of hospitalization for heart attack, stroke, or heart failure, according to a study published on the Canadian Medical Association Journal.

The Institute for Safe Medication Practices (ISMP) continues to receive reports of dose measurement confusion with HumuLIN R U-500 concentrated insulin injection, according to a recent safety alert from the agency.

The use of electronic health records (EHRs) saved more than 3% in ambulatory health costs but did not reduce overall inpatient costs, according to a new study.

The new update to the 2009 American Society of Clinical Oncology (ASCO) guideline on the pharmacologic interventions for breast cancer risk reduction now lists aromatase inhibitor exemestane (Aromasin, Pfizer) as an option for postmenopausal women for primary risk reduction that are at an increased risk of developing invasive breast cancer.

With 40% of drugs in this country coming from other nations and 80% of active ingredient manufacturers located outside the United States, last year Congress gave FDA new powers to oversee those products.

A nonprofit dedicated to ensuring online pharmacy safety, whose roots date back to an informal advocacy group started 4 years ago, was this week officially chartered in Washington, D.C.